ArticleIJID regions2025
Tuberculosis treatment outcomes and their related factors in patients with tuberculosis treated at the Antituberculosis Center of Brazzaville, Republic of Congo.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-tuberculosis drug-induced hepatotoxicity among patients undergoing tuberculosis treatment at the Antituberculosis Center of Brazzaville, Republic of Congo.IJID regions · 2026Article
- Patient-related diagnostic delay and risk of unfavorable treatment outcomes among pulmonary tuberculosis patients at the antituberculosis center of Brazzaville, Republic of Congo.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tuberculosis (TB) treatment outcome is one of the key indicators to evaluate the performance of TB control programs. This study aims to assess TB treatment outcomes and their related associated factors in patients treated at the Antituberculosis Center of Brazzaville, Republic of Congo. Methods: A prospective cohort study was conducted at the Antituberculosis Center of Brazzaville from July 2022 to August 2023, involving 305 patients with pulmonary TB diagnosed with the GenXpert MTB/RIF assay. These patients were closely monitored using acid-fast bacillus microscopy while receiving treatment based on whether they were drug-sensitive (DS) or drug-resistant. Sputum samples from patients who were DS were analyzed at 2, 5, and 6 months, whereas patients who were multi-drug-resistant (MDR) underwent a monthly sputum analysis for 9 months. Results: The overall successful treatment rate was 80.3%, with 70.8% of patients cured and 9.5% completing treatment. Conversely, 19.7% experienced unsuccessful outcomes, including 13.4% loss to follow-up, 3.6% deaths, and 1.6% treatment failures. The treatment success in individuals co-infected with HIV was 46.7% (seven of 15), whereas it was 42% (eight in 19) in patients who were MDR. HIV-negative status (adjusted odds ratio = 5.11; 95% confidence interval: 1.73-13.44) and DS-TB (adjusted odds ratio = 8.29; 95% confidence interval: 3.17-21.04) were associated with increased success of treatment outcome. Conclusions: The overall TB treatment success rate was below the World Health Organization End TB Strategy threshold, with a high proportion of patients lost to follow-up and a low treatment success in patients with TB/HIV and those who were MDR. The findings highlight the need to enhance supervision, improve directly observed treatment short course monitoring, and develop strategies to minimize patients lost to follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.